Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) and Novartis (NYSE: NVS ) enjoy little competition for their vision-improving drugs Eylea and Lucentis. As a result, sales of Eylea grew to more than $1.8 billion last year, just two years after winning FDA approval in 2011, and sales of Novartis and Roche’s (NASDAQOTH: RHHBY ) Lucentis, which was first approved in 2006, have climbed to more than … Continue reading Stocks to Watch on Monday: Regeneron Pharmaceuticals (NASDAQ:REGN), Symantec Corporation (NASDAQ:SYMC), Hewlett-Packard (NYSE:HPQ), First Solar (NASDAQ:FSLR)